Antibodies targeting PD-1 have demonstrated clinical benefits in multiple cancer types, such as advanced melanoma, non-small-cell lung cancer, renal cell carcinoma and urothelial carcinoma [4–7]. Here, PDCD1 is linked to melanoma.